Pictet Asset Management
ACAD icon

Pictet Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Pictet Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.1M Sell
1,983,198
-42,846
-2% -$943K 0.05% 337
2026
Q1 		$44.7M Buy
2,026,044
+478,941
+31% +$11.4M 0.05% 331
2025
Q4 		$41.5M Buy
1,547,103
+84,055
+6% +$2.01M 0.04% 359
2025
Q3 		$31.2M Sell
1,463,048
-121,486
-8% -$2.87M 0.03% 425
2025
Q2 		$34.4M Buy
1,584,534
+1,149,578
+264% +$21.4M 0.04% 387
2025
Q1 		$7.42M Sell
434,956
-32,487
-7% -$590K 0.01% 728
2024
Q4 		$8.58M Sell
467,443
-37,281
-7% -$602K 0.01% 704
2024
Q3 		$7.92M Sell
504,724
-7,966
-2% -$133K 0.01% 714
2024
Q2 		$8.33M Sell
512,690
-795,068
-61% -$12.8M 0.01% 669
2024
Q1 		$24M Sell
1,307,758
-153,474
-11% -$3.8M 0.03% 460
2023
Q4 		$45.8M Buy
1,461,232
+109,635
+8% +$2.62M 0.05% 326
2023
Q3 		$28.2M Buy
+1,351,597
New +$36.7M 0.03% 384

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pictet Asset Management's ACAD Position: Q2 2026 in Review

Pictet Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 2.1% in Q2 2026, selling an estimated $943K and leaving 1,983,198 shares worth $50.1M. The position accounts for 0.05% of the portfolio, ranked #337.

Pictet Asset Management first reported a position in ACAD in Q3 2023 and has held it in 12 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Pictet Asset Management held 1,983,198 shares of Acadia Pharmaceuticals worth $50.1M as of Q2 2026.
  • Pictet Asset Management sold 42,846 Acadia Pharmaceuticals shares in Q2 2026, an estimated $943K.
  • Acadia Pharmaceuticals made up 0.05% of Pictet Asset Management's portfolio in Q2 2026, its #337 holding.
  • Pictet Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.